Your browser is no longer supported. Please, upgrade your browser.
Oncorus, Inc.
Index- P/E- EPS (ttm)-2.32 Insider Own0.40% Shs Outstand25.75M Perf Week1.44%
Market Cap150.01M Forward P/E- EPS next Y-2.88 Insider Trans39.37% Shs Float25.12M Perf Month-49.55%
Income-56.70M PEG- EPS next Q-0.83 Inst Own77.00% Short Float2.29% Perf Quarter-44.99%
Sales- P/S- EPS this Y-62.40% Inst Trans-2.71% Short Ratio2.80 Perf Half Y-66.96%
Book/sh5.74 P/B0.98 EPS next Y-15.40% ROA-27.50% Target Price31.00 Perf Year-80.70%
Cash/sh5.48 P/C1.03 EPS next 5Y- ROE-36.50% 52W Range5.29 - 37.86 Perf YTD-82.52%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-84.94% Beta-
Dividend %- Quick Ratio12.00 Sales past 5Y- Gross Margin- 52W Low7.75% ATR0.62
Employees56 Current Ratio12.00 Sales Q/Q- Oper. Margin- RSI (14)31.06 Volatility7.13% 7.97%
OptionableYes Debt/Eq0.00 EPS Q/Q34.30% Profit Margin- Rel Volume0.50 Prev Close5.65
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume205.46K Price5.70
Recom1.70 SMA20-19.83% SMA50-35.26% SMA200-54.75% Volume35,957 Change0.88%
Mar-16-21Initiated Maxim Group Buy $35
Oct-27-20Initiated Piper Sandler Overweight $40
Oct-27-20Initiated Jefferies Buy $22
Oct-27-20Initiated Evercore ISI Outperform $35
Nov-29-21 06:13AM  
Nov-23-21 07:00AM  
Nov-17-21 07:00AM  
Nov-12-21 03:11PM  
Nov-11-21 07:00AM  
Nov-09-21 08:00AM  
Nov-08-21 10:50AM  
Nov-03-21 07:00AM  
Oct-01-21 08:00AM  
Sep-29-21 10:58AM  
Sep-22-21 10:15AM  
Aug-04-21 07:00AM  
Jul-29-21 07:00AM  
Jul-01-21 05:16AM  
Jun-17-21 07:00AM  
Jun-15-21 07:57AM  
May-27-21 07:05AM  
May-26-21 07:00AM  
May-04-21 07:00AM  
Apr-02-21 05:04AM  
Mar-10-21 07:00AM  
Feb-12-21 09:31AM  
Feb-11-21 10:15PM  
Feb-09-21 05:01PM  
Jan-20-21 07:00AM  
Jan-04-21 07:00AM  
Jan-02-21 03:59AM  
Dec-14-20 08:00AM  
Dec-07-20 08:00AM  
Nov-24-20 08:00AM  
Nov-12-20 07:00AM  
Nov-11-20 07:00AM  
Oct-05-20 04:05PM  
Oct-02-20 11:23AM  
Oct-01-20 07:12PM  
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ashburn TheodorePresident and CEONov 19Option Exercise1.8132,50058,82599,352Nov 22 06:30 AM
Harbin StephenCOO and Chief of StaffNov 16Buy5.7815,00086,70015,000Nov 17 04:05 PM
Harbin StephenCOO and Chief of StaffNov 16Buy5.8015,00086,95515,000Nov 17 04:05 PM
Ashburn TheodorePresident and CEOOct 22Option Exercise1.8143,70779,11066,852Oct 25 05:06 PM
Queva ChristopheCSO and SVP, ResearchJun 02Sale16.6610,656177,52947,626Jun 03 05:15 PM
Queva ChristopheCSO and SVP, ResearchJun 01Sale16.6912,899215,28458,282Jun 03 05:15 PM
Queva ChristopheCSO and SVP, ResearchMay 24Option Exercise1.8135,56164,36571,181May 26 04:31 PM
Queva ChristopheCSO and SVP, ResearchApr 30Sale15.9723,555376,12335,620May 04 05:33 PM
Queva ChristopheCSO and SVP, ResearchApr 28Sale15.2217,990273,80859,175Apr 28 07:32 PM
Queva ChristopheCSO and SVP, ResearchApr 27Sale15.002113,16577,165Apr 28 07:32 PM
Queva ChristopheCSO and SVP, ResearchApr 26Sale15.005481077,376Apr 28 07:32 PM
Ashburn TheodorePresident and CEOApr 07Option Exercise5.324,69924,99923,145Apr 09 04:30 PM
Queva ChristopheCSO and SVP, ResearchApr 06Sale15.015,30079,55377,430Apr 08 04:57 PM
Flynn James EDirectorFeb 17Buy19.00300,0005,700,0001,401,905Feb 18 06:44 PM
Ashburn TheodorePresident and CEODec 31Option Exercise1.811,9003,43918,446Apr 09 04:30 PM